GPhA and Biosimilars Council Praise New Jersey Biosimilars Law
Contact: Steve Arnoff 202.249.7113
WASHINGTON, DC (November 9, 2015) — The Generic Pharmaceutical Association (GPhA) and its Biosimilars Council applaud Gov. Christie for signing New Jersey A. 2477 into law, allowing interchangeable biologic substitution at the pharmacy.
“This year for biosimilars continues to be one of progress and promise,” said Chip Davis, President and CEO, Generic Pharmaceutical Association (GPhA). “We are very pleased that state policymakers in New Jersey and across the country are ensuring pharmaceutical competition and promoting patient access to more affordable medicine.”
Twelve states plus Puerto Rico have enacted these measures in 2015.
About the GPhA Biosimilars Council
The Biosimilars Council, a division of the Generic Pharmaceutical Association (GPhA), works to ensure a positive environment for patient access to biosimilar medicines. The Biosimilars Council is a leading source for information about the safety and efficacy of more affordable alternatives to costly brand biologic medicines. Areas of focus include public and health expert education, strategic partnerships, government affairs, legal affairs and regulatory policy. More information is available at www.biosimilarscouncil.org.
GPhA represents the manufacturers and distributors of finished generic pharmaceuticals, manufacturers and distributors of bulk pharmaceutical chemicals, and suppliers of other goods and services to the generic industry. Generic pharmaceuticals fill 88 percent of the prescriptions dispensed in the U.S. but consume just 28 percent of the total drug spending. Additional information is available at gphaonline.org. Follow us on twitter: @gpha.